Effect of co-administration of the selective 5-HT1A receptor antagonist WAY 100,635 and selective 5-HT1B/1D receptor antagonist GR 127,935 on anxiolytic effect of citalopram in conditioned fear stress in the rat

European Journal of Pharmacology

Volumn 586, Issue 1-3, 2008, Pages 171-178

  Muraki, Ihoko ^a   Inoue, Takeshi ^a   Koyama, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anxiety; Conditioned fear stress; Selective 5 HT1A receptor antagonist; Selective 5 HT1B 1D receptor antagonist; SSRI selective serotonin (5 HT) reuptake inhibitor

Indexed keywords

CITALOPRAM; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BEHAVIOR CONTRACTING; CENTRAL NERVOUS SYSTEM; COMBINATION CHEMOTHERAPY; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; FEAR; LOW DRUG DOSE; MALE; MENTAL STRESS; MONOTHERAPY; MOTOR PERFORMANCE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SINGLE DRUG DOSE; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; BEHAVIOR, ANIMAL; CITALOPRAM; CONDITIONING (PSYCHOLOGY); DATA INTERPRETATION, STATISTICAL; FEAR; MALE; MOTOR ACTIVITY; OXADIAZOLES; PIPERAZINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL; SYNAPTIC TRANSMISSION;

EID: 43549085921     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.040     Document Type: Article

References (60)

1. Artigas F., Perez V., and Alvarez E. Pindolol induces a rapid improvement of patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51 (1994) 248-251
2. Auerbach S.B., and Hjorth S. Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 352 (1995) 597-606
3. Blier P., and de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15 (1994) 220-226
4. Blier P., and Bergeon R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15 (1995) 217-222
5. Bordet R., Thomas P., and Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trials. Am. J. Psychiatry 155 (1998) 1346-1351
6. Borsini F., Podhorna J., and Marazziti D. Do animal models of anxiety predict anxiolytic-like effects of antidepressants?. Psychopharmacology 163 (2002) 121-141
7. Bosker F.J., Klompmakers A.A., and Westenberg H.G.M. Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat. Neuropharmacology 34 (1995) 501-508
8. 1B receptors, as measured by in vivo microdialysis in dorsal hippocampus of conscious rats. Psychopharmacology 117 (1995) 358-363
9. Burghardt N.S., Bush D.E.A., McEwen B.S., and LeDoux J.E. Acute selective serotonin reuptake inhibitors increase conditioned fear expression: blockade with a 5-HT2C receptor antagonist. Biol. Psychiatry 62 (2007) 1111-1118
10. Chaput Y., de Montigny C., and Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 333 (1986) 342-348
11. 4 receptor agonist. Psychopharmacology 188 (2006) 244-251
12. 1B autoreceptors in rat lateral geniculate nucleus. Brain Res. 760 (1997) 238-242
13. 1A receptor antagonists on fluoxetine-induced changes in serotonin in rat frontal cortex. Eur. J. Pharmacol. 345 (1998) 41-46
14. 1A receptors. Neurochem. Res. 21 (1996) 557-562
15. 1A) receptor antagonist WAY100635. Br. J. Pharmacol. 130 (2000) 1713-1719
16. Falzone T.L., Gelman D.M., Young J.I., Grandy D.K., Low M.J., and Rubinstein M. Absence of dopamine D4 receptors results in enhanced reactivity to unconditioned, but not conditioned, fear. Eur. J. Neurosci. 15 (2002) 158-164
17. Fanselow M.S. Conditional and unconditional components of postshock freezing. Pavlovian J. Biol. Sci. 15 (1980) 177-182
18. Fuller R.W. Uptake inhibitors increase extracellular serotonin concentration measured by brain microdialysis. Life Sci. 55 (1994) 163-167
19. 1A autoreceptors in the mechanism of action of serotonergic antidepressant drugs: recent findings from in vivo microdialysis studies. Fundam. Clin. Pharmacol. 10 (1996) 16-27
20. 1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br. J. Pharmacol. 115 (1995) 1064-1070
21. 1B receptors with WAY 100635 and GR 127935. J. Neurochem. 68 (1997) 1159-1163
22. Goodwin G.M., Phil D., Edin F.R.C.P., and Psych F.R.C. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of SSRIs. J. Clin. Psychiatry 57 Suppl. 4 (1996) 9-13
23. Grillon C., Levenson J., and Pine D. A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study. Neuropsychopharmacology 32 (2007) 225-231
24. Harmer C.J., Bhagwagar Z., Perrett D.I., Völlm B.A., Cowen P.J., and Goodwin G.M. Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28 (2003) 148-152
25. Hashimoto S., Inoue T., and Koyama T. Serotonin reuptake inhibitors reduce conditioned fear stress-induced freezing behavior in rats. Psychopharmacology 123 (1996) 182-186
26. Hashimoto S., Inoue T., and Koyama T. The effects of the co-administration of 5-HT1A receptor antagonists with an SSRI in conditioned fear stress-induced freezing behavior. Pharmacol. Biochem. Behav. 58 (1997) 471-475
27. Hashimoto S., Inoue T., and Koyama T. Effects of conditioned fear stress on serotonin neurotransmission and freezing behavior in rats. Eur. J. Pharmacol. 378 1 (1999) 23-30
28. 1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo-a microdialysis study. J. Neurochem. 60 (1993) 776-779
29. Hjorth S. (-) pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur. J. Pharmacol. 303 (1996) 183-186
30. 1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav. Brain Res. 73 (1996) 281-283
31. 1A (auto) receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology 36 (1997) 461-465
32. Hoyer D., and Middlemiss D.N. The pharmacology of the terminal 5-HT autoreceptors in mammalian brain: evidence for species differences. Trends Pharmacol. Sci. 10 (1989) 130-132
33. Inoue T., Tsuchiya K., and Koyama T. Serotonergic activation reduces defensive freezing in the conditioned fear paradigm. Pharmacol. Biochem. Behav. 53 (1996) 825-831
34. Inoue T., Li X.-B., Abekawa T., Kitaichi Y., Izumi T., Nakagawa S., and Koyama T. Selective serotonin reuptake inhibitor reduces conditioned fear through its effect in the amygdala. Eur. J. Pharmacol. 497 (2004) 311-316
35. Inoue T., Nakagawa S., Izumi T., Kitaichi Y., and Koyama T. Effect of combined treatment with noradrenaline and serotonin reuptake inhibitors on conditioned freezing. Eur. J. Pharmacol. 540 (2006) 91-95
36. 1A receptors. Eur. J. Pharmacol. 260 (1994) 243-246
37. 1A receptors in the effects of acute and chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol. Biochem. Behav. 54 (1996) 143-147
38. Leonard B.E. Mechanism of action of antidepressants. CNS Drugs 4 Suppl. 1 (1995) 1-12
39. Leonard B.E. New approaches to the treatment of depression. J. Clin. Psychiatry 57 Suppl. 4 (1996) 26-33
40. 4 receptors. Eur. J. Pharmacol. 574 (2007) 15-19
41. 11C] DASB position emission tomography study. Am. J. Psychiatry 161 5 (2004) 826-835
42. Moret C., and Briley M. Effects of acute and repeated administration of citalopram on extracellular levels of serotonin in rat brain. Eur. J. Pharmacol. 295 (1996) 189-197
43. Muraki I., Inoue T., Hashimoto S., Izumi T., Ito K., Ohmori T., and Koyama T. Effect of subchronic lithium treatment on anxiolytic-like effect of citalopram and MKC-242 in conditioned fear stress in the rat. Eur. J. Pharmacol. 383 (1999) 223-229
44. Muraki I., Inoue T., Hashimoto S., Izumi T., Ito K., and Koyama T. Effects of subchronic lithium treatment on citalopram-induced increases in extracellular concentrations of serotonin in the medial prefrontal cortex. J. Neurochem. 76 (2001) 490-497
45. Ohmori T., Abekawa T., Muraki A., and Koyama T. Competitive and noncompetitive NMDA antagonists block sensitization to methamphetamine. Pharmacol. Biochem. Behav. 48 (1994) 587-591
46. Rollema H., Clarke T., Sprouse J.S., and Schulz D.W. Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J. Neurochem. 67 (1996) 2204-2207
47. 1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci. Lett. 219 (1996) 123-126
48. Rutter J.J., Gundlah C., and Auerbach S.B. Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine. Neurosci. Lett. 171 (1994) 183-186
49. Sánchez C., and Hytell J. Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell. Mol. Neurobiol. 19 4 (1999) 467-489
50. Schreiber R., Melon C., and De Vry J. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test. Psychopharmacology (Berl) 135 (1998) 383-391
51. Sharp T., Bramwell S.R., Hjorth S., and Grahame-Smith D.G. Pharmacological characterization of 8-OHDPAT induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br. J. Pharmacol. 98 (1989) 989-997
52. 1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br. J. Pharmacol. 121 (1997) 941-946
53. Skingle M., Sleight A.J., and Fenuik W. Effect of the 5-HT1D receptor antagonist GR 127935 on extracellular levels of 5-HT in the Guinea-pig frontal cortex as measured by microdialysis. Neuropsychopharmacology 34 (1995) 377-382
54. Takahashi H., Yahata N., Koeda M., Takano A., Asai K., Suhara T., and Okubo Y. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. NeuroImage 27 (2005) 991-1001
55. Thomas D.R., Nelson D.R., and Johnson A.M. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor. Psychopharmacology (Berl) 93 (1987) 193-200
56. 1A receptor and of catecholaminergic systems in the behavioral response to 8-hydroxy-2-(di-n-propylamino) tetralin in the rat. Eur. J. Pharmacol. 106 (1984) 271-272
57. *D: implications for clinical practice. Am. J. Psychiatry 163 (2006) 28-40
58. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., and Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response?. J. Clin. Psychopharmacol. 17 (1997) 446-450
59. Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., and Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J. Clin. Psychopharmacol. 18 (1998) 441-446
60. Zohar J., and Westenberg H.G.M. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. 101 Suppl. 403 (2000) 39-49